Neurological toxicity due to antimonial treatment for refractory visceral leishmaniasis

dc.contributor.authorMaristany Bosch, Marta
dc.contributor.authorCuervo Requena, Guillermo
dc.contributor.authorMatas Martín, Elisabet
dc.contributor.authorVeciana de las Heras, Misericordia
dc.contributor.authorPedro Pérez, Jordi
dc.contributor.authorMartínez Yélamos, Sergio
dc.contributor.authorSabé, Nuria
dc.date.accessioned2021-10-21T12:52:50Z
dc.date.available2021-10-21T12:52:50Z
dc.date.issued2021-01-01
dc.date.updated2021-10-21T08:06:48Z
dc.description.abstractIntroduction: Although pentavalent antimonials are no longer considered the first-line therapy for visceral leishmaniasis in the developed world, they are still used in certain geographical areas and in refractory cases. These drugs have a great number of adverse effects; however, neurological toxicity has been rarely reported. Case report: We present a 56-year-old woman who required long-term treatment with antimonial drugs due to refractory visceral leishmaniasis and presented clinically with tremor of extremities, myoclonus, gait disturbances and epileptic seizures. The EEG showed increased beta rhythms and generalized epileptogenic activity. She had a slow but favorable response after the withdrawal of antimonials and the initiation of anticonvulsant therapy. Conclusion: Severe but reversible neurological toxicity is a rare adverse effect of prolonged antimonial treatment. More EEG record data are needed to support the suspicion of a possible increase of beta rhythms in this situation. (C) 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V.
dc.format.extent4 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2467-981X
dc.identifier.urihttps://hdl.handle.net/2445/180720
dc.language.isoeng
dc.publisherElsevier BV
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.cnp.2021.03.008
dc.relation.ispartofClinical Neurophysiology Practice, 2021, vol. 6, p. 164-167
dc.relation.urihttps://doi.org/10.1016/j.cnp.2021.03.008
dc.rightscc by-nc-nd (c) Maristany Bosch, Marta et al, 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationLeishmaniosi
dc.subject.classificationTerapèutica
dc.subject.classificationToxicitat dels medicaments
dc.subject.otherLeishmaniasis
dc.subject.otherTherapeutics
dc.subject.otherDrug toxicity
dc.titleNeurological toxicity due to antimonial treatment for refractory visceral leishmaniasis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
1-s2.0-S2467981X21000214-main.pdf
Mida:
1.5 MB
Format:
Adobe Portable Document Format